Relationship between sofosbuvir + velpatasvir + ribavirin combination therapy and drug resistance mutation for DAA treatment failure cases

Relationship between sofosbuvir + velpatasvir + ribavirin combination therapy and drug resistance mutation for DAA treatment failure cases - Relationship between sofosbuvir + velpatasvir + ribavirin combination therapy and drug resistance mutation for DAA treatment failure cases

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040609

Enrollment

Registered

2020-06-01

Start date

2019-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients over 20 years old

Exclusion criteria

Exclusion criteria: Patients who cannot regularly visit the outpatient department of hepatobiliary-pancreatic medicine. Patients with hepatocellular carcinoma. Patients with impaired renal function (eGFR 30 ml / min / less than 1.73 m2). Patients who are allergic to this drug. Patients who are taking contraindications for this study drugs. Patients who are judged by the attending physician to possibly impair patient safety.

Design outcomes

Primary

Measure	Time frame
The significance of this study is to collect clinical data on treatment and to clarify the association with drug resistance mutations.	—

Countries

Japan

Contacts

Public ContactAkihiro Tamori

School of Medicine and Graduate school of Medicine Osaka City University Department of Hepatology

atamori@med.osaka-cu.ac.jp06-6645-3905

Outcome results